WSJ – Puget Technologies (OTCBB: PUGE) revealed today its new subsidiary, Cannabis BioTech is in negotiations with a leading international medical marijuana consultant to round out its research and development team.
Through his California based research firm, this prominent international authority designs and builds effective and efficient programs to assist dispensaries and medical cannabis companies to produce superior products.
Amid changing attitudes about marijuana, Cannabis Biotech is dedicated to developing medicinal cannabinoid delivery options using the latest scientific advances. The product development being conducted by Cannabis BioTech is expected to add to the growing body of data demonstrating marijuana’s medicinal benefits.
President and CEO of Puget Technologies Ron Leyland said, “We are very close to completing negotiations which will result in adding more strength to our scientific team and accelerating the development of our line of alternate delivery options.” He added, “The 1.7 Billion dollar U.S. medical marijuana market is expected to quadruple in size during the next five years, and having such expertise onboard will ensure our frontrunner position in the industry.”